1. AB0356 TARGETING THE RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLAST VIA CYCLIN DEPENDENT KINASE INHIBITION (TRAFIC): A PHASE 1B STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE OF SELICICLIB FOR REPURPOSING IN RHEUMATOID ARTHRITIS. (2nd June 2020) Authors: Pratt, A.; Siebert, S.; Cole, M.; Stocken, D.; Kelly, S.; Shaikh, M.; Cranston, A.; Morton, M.; Walker, J.; Frame, S.; Ng, W. F.; Buckley, C.; Mcinnes, I.; Filer, A.; Isaacs, J. D. Journal: Annals of the rheumatic diseases Issue: Volume 79(2020)Supplement 1 Page Start: 1478 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. GSK3 makes a comeback. (June 2001) Authors: Biondi, R.; Frame, S.; Thomas, G.; Cohen, P. Journal: Biochemical Society transactions Issue: Volume 29:Number 3(2001) Page Start: A59 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia. (December 2016) Authors: Moureau, S.; Pohler, E.; Kroboth, K.; Saladino, C.; MacKay, C.; Hollick, J.; Zheleva, D.; Frame, S.; Blake, D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S117 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗